Search

Your search keyword '"Corradini, S"' showing total 1,247 results
Start Over Author "Corradini, S"
1,247 results on '"Corradini, S"'

2. Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment

Author

Chianelli, M., Busetto, L., Vettor, R., Annibale, B., Paoletta, A., Papini, E., Albanese, A., Carabotti, M., Casarotto, D., De Pergola, G., Disoteo, O. E., Grandone, I., Medea, G., Nisoli, E., Raffaelli, M., Schiff, S., Vignati, F., Cinquini, M., Gonzalez-Lorenzo, M., Fittipaldo, V. A., Minozzi, S., Monteforte, M., Tralongo, A. C., Novizio, R., Persichetti, A., Samperi, I., Scoppola, A., Borretta, G., Carruba, M., Carbonelli, M. G., De Luca, M., Frontoni, S., Corradini, S. G., Muratori, F., and Attanasio, R.

Published
2024
Full Text
View/download PDF

4. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial

Author

Fink, C.A., Ristau, J., Buchele, C., Klüter, S., Liermann, J., Hoegen-Saßmannshausen, P., Sandrini, E., Lentz-Hommertgen, A., Baumann, L., Andratschke, N., Baumgartl, M., Li, M., Reiner, M., Corradini, S., Hörner-Rieber, J., Bonekamp, D., Schlemmer, H.-P., Belka, C., Guckenberger, M., Debus, J., and Koerber, S.A.

Published
2024
Full Text
View/download PDF

6. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial

Author

Hoegen, P., Zhang, K. S., Tonndorf-Martini, E., Weykamp, F., Regnery, S., Naumann, P., Lang, K., Ristau, J., Körber, S. A., Dreher, C., Buchele, C., Rippke, C., Renkamp, C. K., Paul, K. M., König, L., Büsch, C., Krisam, J., Sedlaczek, O., Schlemmer, H.-P., Niyazi, M., Corradini, S., Debus, J., Klüter, S., and Hörner-Rieber, J.

Published
2022
Full Text
View/download PDF

9. OC.11.7: DAILY DIETARY INTAKE OF SOLUBLE FIBER IS ASSOCIATED WITH CHOLESTATIC LIVER INJURY ANDWORSENING LIVER FUNCTION IN LIVER TRANSPLANT CANDIDATES WITH CIRRHOSIS AND PORTOSYSTEMIC SHUNTS

Author

Parisse, S., primary, Carnevale, S., additional, Ferri, F., additional, Mischitelli, M., additional, Damato, E., additional, Lucatelli, P., additional, Corona, M., additional, Cantafora, A., additional, Muscaritoli, M., additional, and Ginanni Corradini, S., additional

Published
2024
Full Text
View/download PDF

11. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial

Author

Fink, C A, Ristau, J, Buchele, C, Klüter, S, Liermann, J, Hoegen-Saßmannshausen, P, Sandrini, E, Lentz-Hommertgen, A, Baumann, L, Andratschke, N, Baumgartl, M, Li, M, Reiner, M, Corradini, S, Hörner-Rieber, J, Bonekamp, D, Schlemmer, H-P, Belka, C, Guckenberger, M, Debus, J, Koerber, S A, Fink, C A, Ristau, J, Buchele, C, Klüter, S, Liermann, J, Hoegen-Saßmannshausen, P, Sandrini, E, Lentz-Hommertgen, A, Baumann, L, Andratschke, N, Baumgartl, M, Li, M, Reiner, M, Corradini, S, Hörner-Rieber, J, Bonekamp, D, Schlemmer, H-P, Belka, C, Guckenberger, M, Debus, J, and Koerber, S A

Abstract

BACKGROUND Due to superior image quality and daily adaptive planning, MR-guided stereotactic body radiation therapy (MRgSBRT) has the potential to further widen the therapeutic window in radiotherapy of localized prostate cancer. This study reports on acute toxicity rates and patient-reported outcomes after MR-guided adaptive ultrahypofractionated radiotherapy for localized prostate cancer within the prospective, multicenter phase II SMILE trial. MATERIALS AND METHODS A total of 69 patients with localized prostate cancer underwent MRgSBRT with daily online plan adaptation. Inclusion criteria comprised a tumor stage ≤ T3a, serum PSA value ≤ 20 ng/ml, ISUP Grade group ≤ 4. A dose of 37.5 Gy was prescribed to the PTV in five fractions on alternating days with an optional simultaneous boost of 40 Gy to the dominant intraprostatic lesion defined by multiparametric MRI. Acute genitourinary (GU-) and gastrointestinal (GI-) toxicity, as defined by CTCAE v. 5.0 and RTOG as well as patient-reported outcomes according to EORTC QLQ-C30 and -PR25 scores were analyzed at completion of radiotherapy, 6 and 12 weeks after radiotherapy and compared to baseline symptoms. RESULTS There were no toxicity-related treatment discontinuations. At the 12-week follow-up visit, no grade 3 + toxicities were reported according to CTCAE. Up until the 12-week visit, in total 16 patients (23 %) experienced a grade 2 GU or GI toxicity. Toxicity rates peaked at the end of radiation therapy and subsided within the 12-week follow-up period. At the 12-week follow-up visit, no residual grade 2 GU toxicities were reported and 1 patient (1 %) had residual grade 2 enteritic symptoms. With exception to a significant improvement in the emotional functioning score following MRgSBRT, no clinically meaningful changes in the global health status nor in relevant subscores were reported. CONCLUSION Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without a

Published
2024

12. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

Author

Rendina, M, Barone, M, Lillo, C, Trapani, S, Masiero, L, Trerotoli, P, Puoti, F, Lupo, L, Tandoi, F, Agnes, S, Grieco, A, Andorno, E, Marenco, S, Giannini, E, Baccarani, U, Toniutto, P, Carraro, A, Colecchia, A, Cescon, M, Morelli, M, Cillo, U, Burra, P, Angeli, P, Colledan, M, Fagiuoli, S, De Carlis, L, Belli, L, De Simone, P, Carrai, P, Di Benedetto, F, De Maria, N, Ettorre, G, Giannelli, V, Gruttadauria, S, Volpes, R, Corsale, S, Mazzaferro, V, Bhoori, S, Romagnoli, R, Martini, S, Rossi, G, Caccamo, L, Donato, M, Rossi, M, Ginanni Corradini, S, Spada, M, Maggiore, G, Tisone, G, Lenci, I, Vennarecci, G, Tortora, R, Vivarelli, M, Svegliati Baroni, G, Zamboni, F, Mameli, L, Tafuri, S, Simone, S, Gesualdo, L, Cardillo, M, Di Leo, A, Rendina M., Barone M., Lillo C., Trapani S., Masiero L., Trerotoli P., Puoti F., Lupo L. G., Tandoi F., Agnes S., Grieco A., Andorno E., Marenco S., Giannini E. G., Baccarani U., Toniutto P., Carraro A., Colecchia A., Cescon M., Morelli M. C., Cillo U., Burra P., Angeli P., Colledan M., Fagiuoli S., De Carlis L., Belli L., De Simone P., Carrai P., Di Benedetto F., De Maria N., Ettorre G. M., Giannelli V., Gruttadauria S., Volpes R., Corsale S., Mazzaferro V., Bhoori S., Romagnoli R., Martini S., Rossi G., Caccamo L., Donato M. F., Rossi M., Ginanni Corradini S., Spada M., Maggiore G., Tisone G., Lenci I., Vennarecci G., Tortora R., Vivarelli M., Svegliati Baroni G., Zamboni F., Mameli L., Tafuri S., Simone S., Gesualdo L., Cardillo M., Di Leo A., Rendina, M, Barone, M, Lillo, C, Trapani, S, Masiero, L, Trerotoli, P, Puoti, F, Lupo, L, Tandoi, F, Agnes, S, Grieco, A, Andorno, E, Marenco, S, Giannini, E, Baccarani, U, Toniutto, P, Carraro, A, Colecchia, A, Cescon, M, Morelli, M, Cillo, U, Burra, P, Angeli, P, Colledan, M, Fagiuoli, S, De Carlis, L, Belli, L, De Simone, P, Carrai, P, Di Benedetto, F, De Maria, N, Ettorre, G, Giannelli, V, Gruttadauria, S, Volpes, R, Corsale, S, Mazzaferro, V, Bhoori, S, Romagnoli, R, Martini, S, Rossi, G, Caccamo, L, Donato, M, Rossi, M, Ginanni Corradini, S, Spada, M, Maggiore, G, Tisone, G, Lenci, I, Vennarecci, G, Tortora, R, Vivarelli, M, Svegliati Baroni, G, Zamboni, F, Mameli, L, Tafuri, S, Simone, S, Gesualdo, L, Cardillo, M, Di Leo, A, Rendina M., Barone M., Lillo C., Trapani S., Masiero L., Trerotoli P., Puoti F., Lupo L. G., Tandoi F., Agnes S., Grieco A., Andorno E., Marenco S., Giannini E. G., Baccarani U., Toniutto P., Carraro A., Colecchia A., Cescon M., Morelli M. C., Cillo U., Burra P., Angeli P., Colledan M., Fagiuoli S., De Carlis L., Belli L., De Simone P., Carrai P., Di Benedetto F., De Maria N., Ettorre G. M., Giannelli V., Gruttadauria S., Volpes R., Corsale S., Mazzaferro V., Bhoori S., Romagnoli R., Martini S., Rossi G., Caccamo L., Donato M. F., Rossi M., Ginanni Corradini S., Spada M., Maggiore G., Tisone G., Lenci I., Vennarecci G., Tortora R., Vivarelli M., Svegliati Baroni G., Zamboni F., Mameli L., Tafuri S., Simone S., Gesualdo L., Cardillo M., and Di Leo A.

Abstract

Introduction: The study of immune response to SARSCoV-2 infection in different solid organ transplant settings represents an opportunity for clarifying the interplay between SARS-CoV-2 and the immune system. In our nationwide registry study from Italy, we specifically evaluated, during the first wave pandemic, i.e., in non-vaccinated patients, COVID-19 prevalence of infection, mortality, and lethality in liver transplant recipients (LTRs), using non-liver solid transplant recipients (NL-SOTRs) and the Italian general population (GP) as comparators. Methods: Case collection started from February 21 to June 22, 2020, using the data from the National Institute of Health and National Transplant Center, whereas the data analysis was performed on September 30, 2020.To compare the sex- and age-adjusted distribution of infection, mortality, and lethality in LTRs, NL-SOTRs, and Italian GP we applied an indirect standardization method to determine the standardized rate. Results: Among the 43,983 Italian SOTRs with a functioning graft, LTRs accounted for 14,168 patients, of whom 89 were SARS-CoV-2 infected. In the 29,815 NL-SOTRs, 361 cases of SARS-CoV-2 infection were observed. The geographical distribution of the disease was highly variable across the different Italian regions. The standardized rate of infection, mortality, and lethality rates in LTRs resulted lower compared to NL-SOTRs [1.02 (95%CI 0.81-1.23) vs. 2.01 (95%CI 1.8-2.2); 1.0 (95%CI 0.5-1.5) vs. 4.5 (95%CI 3.6-5.3); 1.6 (95%CI 0.7-2.4) vs. 2.8 (95%CI 2.2-3.3), respectively] and comparable to the Italian GP. Discussion: According to the most recent studies on SOTRs and SARS-CoV-2 infection, our data strongly suggest that, in contrast to what was observed in NL-SOTRs receiving a similar immunosuppressive therapy, LTRs have the same risk of SARS-CoV-2 infection, mortality, and lethality observed in the general population. These results suggest an immune response to SARS-CoV-2 infection in LTRS that is different fr

Published
2023

15. A COMPARISON BETWEEN 2D AND 3D GAN FOR RECTUM AND BLADDER AUTO-SEGMENTATION ON 0.35 T MR IMAGES

Author

Vagni, M., primary, Tran, H.E., additional, Romano, A., additional, Boldrini, L., additional, Chiloiro, G., additional, Landry, G., additional, Kurz, C., additional, Corradini, S., additional, Kawula, M., additional, Lombardo, E., additional, Petridis, K. Zormpas, additional, Gambacorta, M.A., additional, Indovina, L., additional, Belka, C., additional, Valentini, V., additional, Placidi, L., additional, and Cusumano, D., additional

Published
2023
Full Text
View/download PDF

18. Outcomes of MR-Guided Stereotactic Body Radiotherapy (MRgSBRT) for Adrenal Metastases: A Multi-Institutional Pooled Analysis

Author

Ugurluer, G., primary, Schneiders, F.L., additional, Corradini, S., additional, Boldrini, L., additional, Kotecha, R., additional, Kelly, P., additional, Portelance, L., additional, Camilleri, P., additional, Ben-David, M.A., additional, Poiset, S.J., additional, Marschner, S., additional, Panza, G., additional, Kutuk, T., additional, Palacios, M., additional, Mustafayev, T. Zoto, additional, Atalar, B., additional, Senan, S., additional, and Ozyar, E., additional

Published
2023
Full Text
View/download PDF

19. Early post-treatment changes in body composition parameters are associated with overall survival and need of transplantation in cirrhotic patients with HCC undergoing locoregional treatments

Author

Parisse, S., primary, Mieli, M., additional, Ponzo, M., additional, Rocco, B., additional, Poli, E., additional, Pintore, A., additional, Ferri, F., additional, De Santis, A., additional, Lucatelli, P., additional, Corona, M., additional, Melandro, F., additional, Mennini, G., additional, Rossi, M., additional, Lai, Q., additional, and Corradini, S. Ginanni, additional

Published
2023
Full Text
View/download PDF

20. A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption

Author

Mancina RM, Ferri F, Farcomeni A, Molinaro A, Maffongelli A, Mischitelli M, Poli E, Parlati L, Burza MA, De Santis A, Attilia F, Rotondo C, Rando MM, Attilia ML, Ceccanti M, and Ginanni Corradini S

Subjects
alcoholic cirrhosis, PNPLA3, CD14, predictive score, Medicine (General), R5-920, Genetics, QH426-470
Abstract

Rosellina Margherita Mancina,1,* Flaminia Ferri,2,* Alessio Farcomeni,3 Antonio Molinaro,1 Angela Maffongelli,4 Monica Mischitelli,2 Edoardo Poli,2 Lucia Parlati,5 Maria Antonella Burza,6 Adriano De Santis,2 Fabio Attilia,2 Claudia Rotondo,2 Maria Margherita Rando,2 Maria Luisa Attilia,2 Mauro Ceccanti,2 Stefano Ginanni Corradini2 1Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at the University of Gothenburg, Wallenberg Laboratory, Göteborg, Sweden; 2Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 3Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; 4Department of General Surgery, Urgency and Organ Transplantation, University Hospital “Paolo Giaccone”, University of Palermo, Palermo, Italy; 5Hepatology Department, Université Paris Descartes, Cochin Hospital, APHP, Paris, France; 6Department of Medicine, Division of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden *These authors contributed equally to this work Background: Alcoholic cirrhosis represents 1% of all cause-of-deaths worldwide. Its incidence is higher in males and results from the combination of environmental and genetic factors. Among all the genetic determinants of alcoholic cirrhosis, the patatin-like phospholipase domain protein 3 (PNPLA3) rs738409 represents the most widely validated determinant. Recent cross-sectional studies on alcohol abusers identified transmembrane-6 superfamily member 2 (TM6SF2) rs58542926, membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738, and cluster of differentiation 14 (CD14) rs2569190 as new genetic risk factors for alcoholic cirrhosis. We aimed to develop a gene-based risk score to predict the incidence of alcoholic cirrhosis in males with at-risk alcohol consumption.Materials and methods: A total of 416 male at-risk alcohol drinkers were retrospectively examined. The association between alcoholic cirrhosis incidence and PNPLA3, CD14, TM6SF2, and MBOAT7 variants was tested. Age at onset of at-risk alcohol consumption, age, and body mass index (BMI) were included as covariates to determine the prediction score for alcoholic cirrhosis incidence by evaluating time-dependent receiver operating characteristic curves.Results: We found that PNPLA3, CD14, and TM6SF2 were associated with alcoholic cirrhosis prevalence. PNPLA3 and CD14 were also associated with its incidence. The best predictive score formula was (age at onset of at-risk alcohol consumption × 0.1) + (number of CD14 allele T) + (number of PNPLA3 allele M) + (BMI × 0.1). A threshold of 7.27 was identified as cutoff for the predictive risk of alcoholic cirrhosis development in 36 years from the onset of at-risk alcohol consumption with 70.1% sensitivity and 78.7% specificity.Conclusion: We developed the first score for alcoholic cirrhosis prediction that combines clinical and genetic factors. Keywords: alcoholic cirrhosis, PNPLA3, CD14, predictive score

Published
2019

27. PO-1497 MRgSBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis

Author

D'Aviero, A., primary, Boldrini, L., additional, Romano, A., additional, Chiloiro, G., additional, Corradini, S., additional, De Luca, V., additional, Verusio, V., additional, Castelluccia, A., additional, Alitto, A.R., additional, Catucci, F., additional, Grimaldi, G., additional, Trapp, C., additional, Hörner-Rieber, J., additional, Marchesano, D., additional, Frascino, V., additional, Mattiucci, G.C., additional, Valentini, V., additional, Gentile, P., additional, and Gambacorta, M.A., additional

Published
2023
Full Text
View/download PDF

34. Volcanic Emissions, Plume Dispersion, and Downwind Radiative Impacts Following Mount Etna Series of Eruptions of February 21–26, 2021

Author

Sellitto, P., primary, Salerno, G., additional, Corradini, S., additional, Xueref‐Remy, I., additional, Riandet, A., additional, Bellon, C., additional, Khaykin, S., additional, Ancellet, G., additional, Lolli, S., additional, Welton, E. J., additional, Boselli, A., additional, Sannino, A., additional, Cuesta, J., additional, Guermazi, H., additional, Eremenko, M., additional, Merucci, L., additional, Stelitano, D., additional, Guerrieri, L., additional, and Legras, B., additional

Published
2023
Full Text
View/download PDF

36. Transnational trafficking networks of end-of-life vehicles and e-waste

Author

Favarin, Serena, Berlusconi, Giulia, Aziani, Alberto, Corradini, S., Favarin S. (ORCID:0000-0002-0841-0317), Berlusconi G., Aziani A. (ORCID:0000-0002-4745-7337), Favarin, Serena, Berlusconi, Giulia, Aziani, Alberto, Corradini, S., Favarin S. (ORCID:0000-0002-0841-0317), Berlusconi G., and Aziani A. (ORCID:0000-0002-4745-7337)

Abstract

Based on case studies and interviews, it appears that the transnational trafficking of various waste types follows distinct paths. However, this information only provides a partial view of the global waste trafficking network, as it has never been studied by combining all the known illegal flows of different waste types. To address this gap, we analysed data from the Basel Convention National Reports to reconstruct networks of countries that engaged in illegal exchanges of end-of-life vehicles, e-waste, or both between 2016 and 2019. Our findings suggest that the structure of these networks and the countries involved in the trafficking vary depending on the waste type, with some similarities. While there are a few reciprocal ties, illegal end-of-life vehicles and e-waste typically move in one direction between countries. Most illegal flows occur from the Global North to the Global South, but trafficking also takes place within each of these regions.

Published
2023

40. Cancer of unknown primary (CUP) through the lens of precision oncology – a single institution perspective

Author

Weiss, L., primary, Heinrich, K., additional, Zhang, D., additional, Dorman, K., additional, Rühlmann, K., additional, Hasselmann, K., additional, Klauschen, F., additional, Kumbrink, J., additional, Jung, A., additional, Rudelius, M., additional, Mock, A., additional, Kunz, W. G., additional, Roessler, D., additional, Beyer, G., additional, Corradini, S., additional, Heinzerling, L., additional, Haas, M., additional, von Bergwelt-Baildon, M., additional, Boeck, S., additional, Heinemann, V., additional, and Westphalen, C. B., additional

Published
2023
Full Text
View/download PDF

41. Final Results from the SAVE-HEART Study - Surface-Based Deep Inspiration Breath-Hold Radiotherapy in Left-Sided Breast Cancer.

Author

Corradini, S., Angelini, L., Gaasch, A., Meattini, I., Braun, M., Harbeck, N., Würstlein, R., Landry, G., Niyazi, M., Pazos, M., Belka, C., and Schönecker, S.

Subjects
*MEDICAL dosimetry, *CARDIOTOXICITY, *RADIATION doses, *BREAST surgery, *CARCINOMA in situ
Abstract

Adjuvant radiotherapy (RT) plays an essential role in the management of early breast cancer (BC) but can lead to cardiovascular and lung toxicities. Recently, RT strategies have been developed to optimize the dose distribution to reduce the risk of treatment-related morbidities. Deep inspiration breath-hold (DIBH) increases the distance between the heart and chest wall, minimizing the radiation dose to intrathoracic organs at risk without compromising target coverage or increasing low dose scatter. This prospective study (SAVE-HEART; German Clinical Trials Register number: DRKS00011213), aimed to compare surface-guided DIBH to free-breathing (FB) in patients with left-sided BC, by evaluating individual cardiovascular risks and treatment plan dosimetry. The study enrolled 585 patients from October 2016 to January 2021 who met the inclusion criteria of having left-sided invasive breast carcinoma or carcinoma in situ after breast conserving surgery or mastectomy and requiring adjuvant RT of the breast/thoracic wall with or without regional lymph nodes. The ability to hold breath for 20 seconds was also a prerequisite. The treatments were either hypofractionated (HF, 40.05 Gy in 15 fractions) or normofractionated (NF, 50.00 Gy in 25 fractions). DIBH was applied using the automatically triggered surface guidance system CatalystTM (C-RAD, Uppsala, Sweden) with audio and video feedback to the patient. CT and surface data were acquired during both DIBH and free-breathing states. The primary endpoint of the study is the comparative evaluation of heart dose reduction by using DIBH. Treatment plan dosimetry was significantly improved with the use of deep inspiration breath-hold compared to free-breathing in both hypofractionated (HF) and normofractionated (NF) regimens. The mean and maximum doses to the heart and the near maximum dose of the left coronary artery (LAD) were significantly reduced by 36-42% in HF and NF plans (P <0.001), while the mean ipsilateral lung dose was reduced by 12-14% (P <0.001). Furthermore, the use of DIBH resulted in a 5% reduction in the cumulative 10-year cardiovascular disease risk (10y-CVD risk) compared to radiotherapy without DIBH (3.59% to 3.41%; P <0.001). To the best of our knowledge, this is the largest prospective study to demonstrate a significant advantage in treatment plan dosimetry for the cardiac and ipsilateral lung dose with surface-guided DIBH compared to FB in patients with left-sided BC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. SMILE: Stereotaktische MRT-geführte Radiotherapie von lokal begrenzten Prostatakarzinomen

Author

Ristau, J., primary, Hörner-Rieber, J., additional, Buchele, C., additional, Klüter, S., additional, Jäkel, C., additional, Baumann, L., additional, Andratschke, N., additional, Garcia Schüler, H., additional, Guckenberger, M., additional, Li, M., additional, Niyazi, M., additional, Corradini, S., additional, Belka, C., additional, Herfarth, K., additional, Debus, J., additional, and Körber, S. A., additional

Published
2022
Full Text
View/download PDF

47. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

Author

Angelico, M., Cillo, U., Fagiuoli, S., Strazzabosco, M., Caraceni, P., Toniutto, P.L., Nanni Costa, A., Salizzoni, Torino M., Romagnoli, R., Bertolotti, G., Patrono, D., De Carlis, L., Slim, A., Mangoni, J.M.E., Rossi, G., Caccamo, L., Antonelli, B., Mazzaferro, V., Regalia, E., Sposito, C., Colledan, M., Corno, V., Tagliabue, F., Marin, S., Vitale, A., Gringeri, E., Donataccio, M., Donataccio, D., Baccarani, U., Lorenzin, D., Bitetto, D., Valente, U., Gelli, M., Cupo, P., Gerunda, G.E., Rompianesi, G., Pinna, A.D., Grazi, G.L., Cucchetti, A., Zanfi, C., Risaliti, A., Faraci, M.G., Tisone, G., Anselmo, A., Lenci, I., Sforza, D., Agnes, S., Di Mugno, M., Avolio, A.W., Ettorre, G.M., Miglioresi, L., Vennarecci, G., Berloco, P., Rossi, M., Ginanni Corradini, S., Molinaro, A., Calise, F., Scuderi, V., Cuomo, O., Migliaccio, C., Lupo, L., Notarnicola, G., Gridelli, B., Volpes, R., Li Petri, S., Zamboni, F., Carbotta, G., Dedola, S., Nardi, A., Marianelli, T., Gavrila, C., Ricci, A., Vespasiano, F., Angelico, Mario, Nardi, Alessandra, Romagnoli, Renato, Marianelli, Tania, Corradini, Stefano Ginanni, Tandoi, Francesco, Gavrila, Caius, Salizzoni, Mauro, Pinna, Antonio D., Cillo, Umberto, Gridelli, Bruno, De Carlis, Luciano G., Colledan, Michele, Gerunda, Giorgio E., Costa, Alessandro Nanni, and Strazzabosco, Mario

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results